Titlebook: Management of Peritoneal Metastases- Cytoreductive Surgery, HIPEC and Beyond; Aditi Bhatt Book 2018 Springer Nature Singapore Pte Ltd. 201

秘密會(huì)議

nique, HIPEC methodologies.Covers individual diseases with a.The widespread acceptance among the?oncology community at large of cytoreductive?surgery and HIPEC as a potentially?curative treatment for peritoneal metastases?has paved the way for innovative new therapies?that could benefit a larger pro

Mettle

anaging peritoneal?metastases. The authors highlight essential?practical issues that surgical oncologists?encounter in their day-to-day practice, and?try to before provide evidence based answers?to address them. All chapters were written?and/or reviewed by leading experts in this?field..978-981-13-3910-3978-981-10-7053-2

Apraxia

Cytoreductive Surgery for Peritoneal Metastases: Principles and Techniquesperiences of experts can guide surgeons on what to resect, how much, how, when, in whom, and how to manage the patient thereafter. A knowledge of the pathophysiology of peritoneal cancer spread forms the basis of providing this treatment and developing innovative therapies for future use.

BOLUS

HIPEC Methodology, Comparison of Techniques, and Drug Regimens: Is There a Need for Standardization?. The aim of this manuscript is to review the rationale, variables, and modalities of intraperitoneal chemotherapy. At the same time, it seeks to offer guidance on the current intraperitoneal chemotherapy regimens and potential directions toward more standardization.

荒唐

Book 2018al?practical issues that surgical oncologists?encounter in their day-to-day practice, and?try to before provide evidence based answers?to address them. All chapters were written?and/or reviewed by leading experts in this?field..

磨碎

祖?zhèn)?/a>

Book 2018 metastases?has paved the way for innovative new therapies?that could benefit a larger proportion of?patients. Much has been and continues to be?published on this subject..This book provides comprehensive reviews?on the various aspects of managing peritoneal?metastases. The authors highlight essenti

ablate

Clinical Trials in CRS and HIPEC: Ongoing Trials and Future DirectivesC in metastatic gastric, ovarian, pancreatic, and other gastrointestinal malignancies has spurred further development of a growing number of prospective clinical trials to study outcomes and survival benefit. This chapter summarizes some of the notable, completed clinical trials and current trials being conducted.

CLOT

Evolving Role of CRS and HIPEC: Current Indicationsgressive locoregional therapy that can prolong the life of selected patients with peritoneal metastases (PM). Initially, all sites of origin of PM were dealt with using the same prognostic variables, and the results were evaluated using the same parameters. Currently, PM secondary to various primary

可耕種

Role of HIPEC in the Prevention of Peritoneal Metastasis from Colorectal, Gastric and Appendiceal Caolorectal and gastric cancers. However, this treatment can be offered only to a small, select group of patients, and even in this select group, only a small proportion can be cured. Hence, prevention of peritoneal metastasis assumes importance. Currently, three approaches are being evaluated to prev